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Abstract
Background: Immunosuppression with calcineurin inhibitors remains the mainstay of treatment after kidney
transplantation; however, long-term use of these drugs may be associated with nephrotoxicity. In this regard, the
current approach is to optimise available immunosuppressive regimens to reduce the calcineurin inhibitor dose while
protecting renal function without affecting the efficacy. The ATHENA study is designed to evaluate renal function in
two regimens: an everolimus and reduced calcineurin inhibitor-based regimen versus a standard treatment protocol
with mycophenolic acid and tacrolimus in de novo kidney transplant recipients.
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Method/Design: ATHENA is a 12-month, multicentre, open-label, prospective, randomised, parallel-group study in de
novo kidney transplant recipients (aged 18 years or older) receiving renal allografts from deceased or living donors.
Eligible patients are randomised (1:1:1) prior to transplantation to one of the following three treatment arms: everolimus
(starting dose 1.5 mg/day; C0 3–8 ng/mL) with cyclosporine or everolimus (starting dose 3 mg/day; C0 3–8 ng/mL) with
tacrolimus or mycophenolic acid (enteric-coated mycophenolate sodium at 1.44 g/day or mycophenolate mofetil at
2 g/day) with tacrolimus; in combination with corticosteroids. All patients receive induction therapy with basiliximab.
The primary objective is to demonstrate non-inferiority of renal function (eGFR by the Nankivell formula) in one of the
everolimus arms compared with the standard group at month 12 post transplantation. The key secondary objective is to
assess the incidence of treatment failure, defined as biopsy-proven acute rejection, graft loss, or death, among the
treatment groups. Other objectives include assessment of the individual components of treatment failure, incidence and
severity of viral infections, incidence and duration of delayed graft function, incidence of indication biopsies, slow graft
function and wound healing complications, and overall safety and tolerability. Exploratory objectives include evaluation
of left ventricular hypertrophy assessed by the left ventricular mass index, evolution of human leukocyte antigen and
non-human leukocyte antigen antibodies, and a cytomegalovirus substudy.
Discussion: As one of the largest European multicentre kidney transplant studies, ATHENA will determine whether a de
novo everolimus-based regimen can preserve renal function versus the standard of care. This study further assesses a
number of clinical issues which impact long-term outcomes post transplantation; hence, its results will have a major
clinical impact.
Trial registration: Clinicaltrials.gov: NCT01843348, date of registration – 18 April 2013; EUDRACT number: 2011-005238-21,
date of registration – 20 March 2012
Keywords: Everolimus, Renal function, Kidney transplantation
Background
The evolution of immunosuppressive regimens over the
past few decades has led to considerable improvement
in acute rejection rates and short-term graft survival [1].
Patient and graft survival at 1 year post transplantation
now exceed 95 % in the case of living donation and 90 %
after deceased donation. However, the long-term out-
comes post kidney transplantation do not show a similar
trend of improvement. At 10 years, graft survival re-
mains about 50 % after deceased donation in the US and
in Europe, with approximately 30 % of patients returning
to dialysis and one of four patients dying with a func-
tioning graft [1, 2]. The lack of improvement in long-
term outcomes is further reflected by the fact that the
number of re-transplants among adult kidney transplant
patients has remained almost unchanged over the last
decade [1].
Currently, calcineurin inhibitors (CNIs), cyclosporine,
and tacrolimus are the cornerstone of immunosuppres-
sive therapy post kidney transplantation [1]. However,
their long-term use may be associated with non-
reversible nephrotoxicity, morphologically characterised
by striped fibrosis, progressive arteriolar hyalinosis, and
ischemic glomerulosclerosis, which is a well-recognised
cause of morbidity in transplant patients [3–5]. Chronic
allograft injury alone accounts for two thirds of kidney
graft failures [6]. Clinical data has shown that lowering the
dose of CNI can improve renal function [5–7]. In this
regard, the focus should be on optimising the currently
available immunosuppressive regimens with the aim of
preserving long-term renal function while maintaining
the efficacy [8]. Several studies with a reduced-dose
CNI and everolimus regimen have shown that it main-
tained efficacy and preserved renal function (Table 1)
[9–33]. In the large randomised A2309 trial, pre-
emptive everolimus therapy was associated with a
greater than 60 % reduction in cyclosporine exposure
while preserving renal function with comparable effi-
cacy to mycophenolic acid and standard-exposure
cyclosporine in de novo kidney transplant patients
[16, 17]. In the ASSET study, an everolimus-facilitated
tacrolimus minimisation strategy achieved good renal
function with an acceptable safety profile without com-
promising efficacy [23]. Moreover, everolimus exerts other
non-immunosuppressive properties, including potential
cardioprotective, anti-malignancy, and antiviral effects
[34–41]. These non-immunosuppressive benefits further
suggest that everolimus-based regimens may be a pre-
ferred approach as cardiovascular disease, malignancy,
and infections account for nearly four out of the five
deaths occurring with functioning grafts [6].
The ATHENA trial is designed to further increase
our knowledge and seek answers relating to the use of
everolimus in CNI minimisation protocols in de novo
kidney transplant patients. The ATHENA study as-
sesses the change in renal function at 12 months post
transplant as the primary objective. The design of the
trial is described here.
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Table 1 Everolimus in kidney transplantation
Study Patients and treatment Design Key results
B156
Nashan et al. [9]
N = 111 de novo patients
EVR (3 mg/day) + basiliximab + steroids
with either full-dose CsA (C0 125–250 ng/mL)
or reduced-dose CsA (C0 50–100 ng/mL)
3-year, phase II, open-label, multicentre,
randomised, parallel-group study
• Efficacy failure was significantly
lower in the reduced-dose CsA
group vs. the full-dose CsA group
at month 6 (3.4 % vs. 15.1 %; p = 0.046),
month 12 (8.6 % vs. 28.3 %; p = 0.012),
and month 36 (17.2 % vs. 35.8 %; p = 0.032)
• Mean CrCL (mL/min) was higher in the
reduced-dose CsA group vs. the full-dose
CsA group at month 6 (59.7 vs. 51.1;
p = 0.009), month 12 (60.9 vs. 53.5;
p = 0.007), and month 36 (56.6 vs. 51.7;
p = 0.436)
B201 N = 588 de novo patients 3-year, randomised, multicentre, parallel-group
study; 1-year, double-blind, double-dummy and
2-year, open-label
• At months 12 and 36, efficacy failure
rates were similar for all groups (p = NS)
• At month 36, creatinine values were
higher in the EVR groups, requiring a
protocol amendment that recommended
lower CsA exposure
• Incidence of CMV infection was significantly
lower at month 12 (p = 0.001) and month
36 (p = 0.0001) in the EVR groups vs. the
MMF group
Vitko et al. [10]
Vitko et al. [11]
EVR 1.5 mg/day or EVR 3 mg/day or MMF
2 g/day; all with standard CsA and steroids
B251
Lorber et al. [12]
N = 583 de novo patients
EVR 1.5 mg/day or EVR 3 mg/day or MMF
2 g/day; all with standard CsA and steroids
3-year, randomised, multicentre, parallel-group,
study; 1-year, double-blind, double-dummy, and
2-year, open-label
• At months 12 and 36, primary efficacy
failure rates were similar for all the arms
(p = NS)
• Incidence of antibody-treated acute
rejection was significantly lower at
month 12 (p = 0.01) and month 36
for the EVR 1.5 arm vs. the MMF arm
(p = 0.014)
• In a subgroup analysis, CsA dose
reduction in the EVR arms resulted in
improved renal function
A2306
Vitko et al. [13]
Tedesco-Silva et al. [14]
N = 237 de novo patients
EVR 1.5 mg/day or EVR 3 mg/day; both with
low-dose CsA ± steroids
1-year, multicentre, randomised, open-label,
parallel-group study
• Median serum creatinine levels were
similar for both the EVR arms (month
6, 133 vs. 132 μmol/L; month 12, 131
vs. 130 μmol/L)
• At month 6 and month 12, efficacy
failure rates were similar for both arms
(p = NS)
A2307
Vitko et al. [13]
Tedesco-Silva et al. [14]
N = 256 de novo patients
EVR 1.5 mg/day or EVR 3 mg/day; both with
low-dose CsA + basiliximab induction ± steroids
1-year, multicentre, randomised, open-label, parallel-
group study
• Median serum creatinine levels were
similar for both the EVR arms (month 6,
130 μmol/L in both arms; month 12, 129
vs. 128 μmol/L)
• At month 6 and month 12, efficacy failure
rates were similar for both arms (p = NS)
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Table 1 Everolimus in kidney transplantation (Continued)
US09
Chan et al. [15]
N = 92 de novo patients
Low-dose tacrolimus vs. standard-dose tacrolimus;
both with EVR 1.5 mg/day + steroids + basiliximab
6-month, prospective, multicentre, open-label,
randomised, parallel-group, exploratory study
• No significant difference in mean serum
creatinine between EVR with either low-
or standard-dose tacrolimus treatment
groups at 6 months (112 vs. 127 μmol/L;
p = 0.114)
• Mean eGFR rate was high and comparable
between the EVR with low- or standard-dose
tacrolimus groups (75.3 vs. 72.5 mL/min,
p = 0.466)
• BPAR and efficacy failure rates were low
and comparable for both treatment arms
A2309
Tedesco-Silva et al. [16]
Cibrik et al. [17]
N = 833 de novo patients
EVR (1.5 mg/day, C0 3–8 ng/mL or 3 mg/day,
C0 6–12 ng/mL) + reduced CsA vs. MPA +
standard CsA
24-month, phase IIIb, multicentre, randomised,
open-label, non-inferiority study
• At month 24, composite efficacy failure
rates were 32.9 %, 26.9 %, and 27.4 % in the
EVR 1.5 mg, EVR 3 mg, and MPA groups,
respectively
• Mean eGFR rate (MDRD; mL/min/1.73 m2)
at month 24 was 52.2, 49.4, and 50.5 in the
three arms, respectively
ZEUS (2418)
Budde et al. [18]
Budde et al. [19]
N = 300 de novo patients
After initial immunosuppression with CsA +
EC-MPS + steroids, patients at 4.5 months post
transplant are randomised (1:1) to either
continue the same regimen or switch to
EVR (C0 6–10 ng/mL) + EC-MPS + steroids
12-month, phase IV, prospective, multicentre,
open-label, randomised study with additional
48-month follow-up
• Adjusted mean cGFR was significantly higher
at month 12 (+9.8 mL/min/1.73 m2; p < 0.0001)
and at 5 years (+5.3 mL/min/1.73 m2; p <0.001)
in the EVR group vs. the CsA group
CALLISTO (A2420)
Albano et al. [20]
Dantal et al. [21]
N = 139 de novo patients
Immediate EVR treatment (day 1 post transplant;
C0 3–8 ng/mL) vs. delayed EVR (week 5; C0
3–8 ng/mL). All patients also received low CsA,
anti-IL-2 receptor induction therapy, and steroids
12-month, prospective, multicentre,
open-label study
• Primary composite efficacy failure at month
3 occurred in 55.4 % patients in the immediate
EVR group vs. 63.5 % in the delayed group
(p = 0.387) while at month 12 the rates were
64.6 % and 66.2 %, respectively (p = 0.860)
• At month 12, median eGFR values were 48
and 49 mL/min/1.73 m2 in the immediate
EVR and delayed EVR groups, respectively
• Incidence of DGF and wound healing
complications were similar between the
treatment groups
CERTES (A2419)/LATAM
(A2423)
Novoa et al. [22]
N = 119; A2419 de novo patients
N = 51; A2423 de novo patients
Initial treatment with EVR (C0 3–8 ng/mL) + CsA +
basiliximab induction + steroids; randomisation
(1:1) at 3 months to either continue the same
regimen with CsA reduction (C2 300–500 ng/mL
in A2419 and 350–450 ng/mL in A2423) or to
start CsA elimination (by month 4 in A2419
and by month 6 in A2423) with EVR
(C0 8–12 ng/mL)
12-month, multicentre, prospective, randomised,
open-label study
• At month 12, eGFR rates were significantly
higher in the CsA-elimination group vs.
the CsA-minimisation group (68.3 vs. 63.6 mL/
min/1.73 m2, p = 0.0289)• Post randomisation,
the incidence of efficacy failure (BPAR, graft
loss, death, loss to follow-up) at 12 months
was comparable in the two groups: 18.9 %
in the CNI-elimination group vs. 17.5 % in the
CNI-minimisation group (p = NS)
ASSET (A2426)
Langer et al. [23]
N = 228 de novo patients
EVR (C0 3–8 mg/mL) with tacrolimus (C0 4–7 ng/mL)
up to month 3; from month 4 either continue the
12-month, open-label, randomised study • At month 12, mean eGFR was higher in the very
low-tacrolimus group vs. the low-tacrolimus group
(difference: 5.3 mL/min/1.73 m2; p = NS)
• Incidence of BPAR from month 4 to month 12
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Table 1 Everolimus in kidney transplantation (Continued)
same low-tacrolimus dose or start very low-
tacrolimus dose (C0 1.5–3 ng/mL)
was non-inferior (p = 0.0014) for the very low-
tacrolimus group vs. the low-tacrolimus group
(2.7 % vs. 1.1 %)
• The incidence of NODM from month 4 to month
12 was numerically lower in the very low-tacrolimus
group vs. the low-tacrolimus group (2.7 % vs. 8.6 %;
p = 0.086).
APOLLO (DE02)
Budde et al. [24]
Budde et al. [25]
N = 93 maintenance patients (≥6 months post
transplant)
EVR (C0 6–10 ng/mL) + EC-MPS ± steroids vs.
standard CNI (CsA C0 80–150 ng/mL or tacrolimus
C0 5–10 ng/mL) + EC-MPS ± steroids
12-month, open-label, prospective, multicentre
study with follow-up at month 60
• Mean time post transplant was 83.5 months with
EVR vs. 70.1 months with CNI
• Adjusted mean eGFR values (Nankivell, mL/min/
1.73 m2) were numerically higher with EVR vs.
CNI at month 12 (61.6 vs. 58.8; p = NS) and at
month 60 (63.0 vs. 57.9; p = NS)
• Using the MDRD formula, adjusted eGFR at month
12 was significantly higher (+4.9 mL/min/1.73 m2)
with EVR vs. CNI (p = 0.030)
• At month 60, for patients who remained on the
study drug, mean eGFR was significantly higher
with EVR vs. CNI (71.6 vs. 60.6; p = 0.005)
EVEREST (IT02)
Salvadori et al. [26]
Ponticelli et al. [27]
N = 285 de novo patients
Standard EVR (C0 3–8 ng/mL) with low CsA
(C2 350–500 ng/mL) vs. high EVR (C0 8–12 ng/mL)
with very low CsA (C2 150–300 ng/mL)
6-month, multicentre, randomised, open-label,
parallel-group study with follow-up at 12 months
and an extension to 24 months
• Death-censored graft survival was significantly
lower with standard EVR vs. the high EVR arm at
month 6 (90.2 % vs. 97.9 %, p = 0.007) and at
month 24 (87.4 % vs. 94.4 %, p = 0.048)
• No significant difference between groups at
months 6 and 24 for mean serum creatinine
levels and incidence of BPAR
A1202
Takahashi et al. [28]
N = 122 de novo patients
EVR (C0 3 to 8 ng/mL) + reduced-dose CsA vs.
MMF (2 g/day) + standard-dose CsA. All patients
receive basiliximab and steroids
12-month, phase III, multicentre, randomised,
open-label, parallel-group, non-inferiority study
• 52 % reduction in CsA exposure was achieved
in the EVR group at month 12
• At month 12, EVR with reduced CsA exposure
was non-inferior to the MMF group for
composite efficacy failure (11.5 % vs. 11.5 %)
• Median eGFR at month 12 was comparable
between the EVR arm vs. the MMF arm
(58.00 vs. 55.25 mL/min/1.73 m2; p = 0.063)
ASCERTAIN (A2413)
Holdaas et al. [29]
N = 398 maintenance patients
Patients ≥6 months post transplant and receiving
CNI ± MPA/azathioprine ± steroid randomised to
either continue the same regimen (control arm)
or switch to a CNI-elimination (EVR C0 8–12 ng/mL),
or a CNI-minimisation by 70–90 % (EVR C0 3–8 ng/mL)
regimen
24-month, phase IV, multicentre, prospective,
randomised, open-label, parallel-group study
• At month 24, mean mGFR was comparable
for all the three arms (p = NS)
• Post-hoc analyses showed that patients with
baseline CrCl >50 mL/min had a significantly
greater increase in mGFR after CNI-elimination
vs. the control arm (difference 11.4 mL/min/
1.73 m2, p = 0.017)
• Study drug discontinuation was significantly
high in the CNI-elimination and CNI-
minimisation arms vs. the control arm
SOCRATES (A2421)
Chadban et al. [30]
N = 126 de novo patientsInitial treatment with CsA +
EC-MPS + steroids for the first 14 days post transplant
then either continue the same regimen (control arm)
or switch to + steroids + EC-MPS and CNI withdrawal,
36-month, prospective, open-label, randomised
controlled trial
• The steroid withdrawal arm was prematurely
terminated due to the high rate of discontinuations
• At month 12, EVR with CNI-withdrawal was
non-inferior to the control arm for mean eGFR
(65.1 vs. 67.1 mL/min/1.73 m2; p = 0.026)
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Table 1 Everolimus in kidney transplantation (Continued)
or EVR (C0 6–10 ng/mL) + CsA reduction + steroid
and EC-MPS withdrawal
• Patients in the EVR with CNI-withdrawal group
experienced a higher rate of BPAR vs. the
control group (31 % vs. 13 %, p = 0.048)
MECANO (NL02)
Bemelman et al. [31]
N = 113 maintenance patients
Initial treatment with CsA + EC-MPS + steroids +
basiliximab induction followed by randomisation
at 6 months to start either CsA +MPA elimination,
or MPA + CsA elimination, or EVR + CsA and MPA
elimination; with steroids
24-month, prospective, open-label, randomised,
multicentre study
• Post conversion, acute rejection rates were
3 % in the CsA group, 22 % in the MPA group,
and 0 % in the EVR group (p <0.009)
• Mean serum creatinine values were significantly
lower at the latest follow-up (14 ± 5 months
after transplantation) in the EVR arm vs. the
CsA group
CENTRAL (ASE01)
Mjörnstedt et al. [32]
N = 204 de novo patients
Initial treatment with CsA + EC-MPS + steroids +
basiliximab induction followed by randomisation
at 7 weeks post transplant to either continue
the same regimen, or convert to EVR
(C0 6–10 ng/mL) + EC-MPS
36-month, open-label, parallel-group study • From week 7 to month 12, change in mGFR
was significantly greater with EVR vs. the CsA
arm (4.9 vs. 0.0 mL/min; p = 0.012; ANCOVA).
• No differences in graft or patient survival for
both the groups
• The 12-month incidence of BPAR was
significantly high in the EVR arm vs. the
CsA arm (27.5 % vs. 11.0 %; p = 0.004)
ANCOVA analysis of covariance, BPAR biopsy-proven acute rejection, C0 trough levels, C2 two hours post-dose, cGFR calculated glomerular filtration rate, CMV cytomegalovirus, CNI calcineurin inhibitors, CrCl creatinine clear-
ance, CsA cyclosporine, DGF delayed graft function, EC-MPS enteric-coated mycophenolate sodium, eGFR glomerular filtration rate, EVR everolimus, IL interleukin, MDRD modification of diet in renal disease, mGFR measured
glomerular filtration rate, MMF mycophenolate mofetil, MPA mycophenolic acid, NODM new-onset diabetes mellitus, NS not significant, vs. versus
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Methods/Design
Study design
ATHENA (Clinicaltrials.gov: NCT01843348; EUDRACT
number: 2011-005238-21) is a 12-month, multicentre, ran-
domised, international, prospective, controlled, open-label
study with three parallel treatment groups in de novo kid-
ney transplant recipients receiving renal allografts from de-
ceased or living donors (protocol version 3, 29 July 2014).
Eligible patients are randomised before transplantation
using a validated system to ensure an unbiased treatment
assignment in a 1:1:1 ratio to receive either everolimus
with a reduced dose of cyclosporine, or everolimus with
tacrolimus, or a standard regimen of mycophenolic acid
with tacrolimus (Fig. 1). All patients receive induction ther-
apy with basiliximab and maintenance steroids. At the time
of randomisation, patients are stratified based on the donor
type (living donor, deceased standard criteria donor, or de-
ceased expanded criteria donor) and the participation of
the recipient in the European Senior Program. The study
protocol and the proposed informed consent form were
reviewed and approved by the national institutional review
boards or independent ethics committees at each centre
and the federal institute for drugs and medical devices
(Additional file 1). Written informed consent was obtained
from all patients. The clinical study was designed and is
conducted in accordance with the ethical principles laid
down in the Declaration of Helsinki.
Study population
The study population comprises de novo adult patients re-
ceiving a primary or secondary kidney transplant from a
deceased or living donor. In the case of second kidney
transplants, patients could be enrolled only if the first graft
loss is due to non-immunological reasons. Patients are not
eligible for the study if they are recipients of an ABO-
incompatible transplants, have pre-existing donor-specific
antibodies (DSA), or have an organ cold ischemia time
longer than 30 h. Patients with pre-existing human
leukocyte antigen (HLA)-antibodies not directed against
the donor and less than 20 % panel reactivity at the time
of transplant were included in the study. Detailed inclu-
sion and exclusion criteria are shown in Table 2.
Study objectives
The primary objective at month 12 post transplantation
is to demonstrate non-inferiority in renal function
assessed by the glomerular filtration rate (Nankivell
formula) [41] in at least one of the everolimus treatment
regimens compared with the standard treatment group
receiving mycophenolic acid and tacrolimus. The key
secondary objective at month 12 is to evaluate the inci-
dence of treatment failure defined as biopsy-proven
acute rejection (BPAR), graft loss, or death among the
treatment groups. Other objectives include assessment
of individual components of treatment failure, incidence
and severity of viral infections (cytomegalovirus (CMV),
BK-virus (BKV)), incidence and duration of delayed graft
function (DGF), incidence of indication biopsies, inci-
dence of slow graft function, incidence of wound healing
complications, and duration of healing. Incidence of
viral infections (CMV and BKV) and changes to the viral
load are closely monitored throughout the study. In
addition, a patient subgroup analysis of CMV-specific T-
cells and NK-cells is conducted in a central laboratory.
Fig. 1 Study design. Steroid dose will be at least 5 mg prednisolone or equivalent, according to centre practice. EC-MPS enteric-coated mycophenolate
sodium. M month, MMF mycophenolate mofetil, MPA mycophenolic acid, RND randomisation, Tx transplantation
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Overall, the safety objectives include assessment of
adverse events (AEs) and serious AEs (SAEs), infections
and discontinuations due to AEs, and laboratory abnor-
malities. Exploratory objectives include evaluation of the
incidence of HLA-antibodies and among those DSA and
non-HLA antibodies (AT1R, ETAR) by treatment group
and its association with acute rejection. HLA-antibodies
including DSA were analysed using single antigen Lumi-
nex technology at baseline and month 12. In addition, left
ventricular (LV) changes are measured by LV hypertrophy
(LVH) assessment by echocardiography measurements.
Detailed objectives of the study are outlined in Table 3.
Immunosuppression
All patients receive induction therapy with basiliximab
dosed at 20 mg intravenously on the day of transplant-
ation and on day 4 post transplantation, as per label
recommendations. Patients are randomised to receive
everolimus at an initial dose of 1.5 mg/day with a reduced
dose of cyclosporine and 3 mg/day with tacrolimus within
the first 24 h post transplantation. Thereafter, the dose of
everolimus is adjusted to the target trough concentration
of 3–8 ng/mL throughout the study period. Treatment
with CNI, tacrolimus, or cyclosporine, is initiated within
the first 24 h post transplantation, and the dose of CNI is
adjusted to maintain the target trough levels, as shown in
Fig. 1. In the control group, patients receive mycophenolic
acid at a dose of 1.44 g/day enteric-coated mycophenolate
sodium or at a dose of 2 g/day mycophenolate mofetil
with a standard dose of tacrolimus. Dose adjustments and
interruptions are allowed for tolerability reasons as defined
in the protocol and are recorded. All patients receive corti-
costeroids at a minimum dose of 5 mg/day prednisolone or
equivalent until month 12. Acute rejections are treated
according to local practice and physicians’ discretion. All
patients who prematurely withdraw from the study are pro-
vided with follow-up medical care/referred for appropriate
ongoing care, as per the local practice.
Concomitant medication
Mandatory CMV prophylactic therapy with valganciclovir
is recommended for at least 3 months in the case of high-
Table 3 Objectives of the ATHENA study
Primary objective
• To demonstrate non-inferiority in renal function (estimated GFR
by the Nankivell formula) in at least one of the everolimus arms
compared with the standard regimen at month 12 post
transplantation
Key secondary objectives
• To assess the incidence of treatment failure (composite of biopsy-
proven acute rejection, graft loss, or death) at month 12 post
transplantation
Other secondary objectives
To evaluate the following:
• GFR by different formulae (CKD-EPI, Cockcroft-Gault and MDRD)
• Incidence of individual efficacy endpoints: biopsy-proven acute
rejection, graft loss, and death
• Incidence and severity of viral infections (CMV, BKV)
• Incidence and duration of delayed graft function
• Incidence of slow graft function defined as serum creatinine
>3.0 mg/dL at day 5
• Incidence of wound healing complications related to the surgery
and the duration of healing
• Overall safety and tolerability (incidence of AEs and serious AEs,
infections, discontinuation due to AEs, and laboratory abnormalities)
at month 12 post transplantation
Exploratory objectives
• To compare HLA- and non-HLA antibody evolution at baseline and
month 12 post transplantation
• To evaluate left ventricular hypertrophy (assessed by LV mass index)
and diastolic dysfunction
• The incidence of donor-specific antibodies by treatment group, and
its association with acute rejection
• Analysis of general immunomodulatory effects on lymphocyte
subpopulations and on the incidence and antigen-specific immune
control of CMV infections
AEs adverse events, BKV BK-virus, CKD-EPI Chronic Kidney Disease Epidemiology
Collaboration, CMV cytomegalovirus, GFR glomerular filtration rate, HLA human
leukocyte antigen, LV left ventricular, MDRD modification of diet in renal disease
Table 2 Key inclusion and exclusion criteria
Key inclusion criteria
• Male or female renal allograft recipients aged18 years or older
• Recipients of a primary or secondary kidney transplant from a
deceased or living unrelated/related donor
• Written informed consent to participate in the study
• Cold ischemia time below 30 hours
• Female patients who are menstruating and capable of conceiving
must test negative for pregnancy before study enrolment and
during the conduct of the study
Key exclusion criteria
• Multi-organ transplant recipients
• Graft loss due to immunological reasons in the first year after
transplantation (in case of secondary transplantation)
• ABO-incompatible transplants
• A current panel reactive antibody level of >20 % (within 4 months
before enrolment) or positive Luminex test for any donor antigen
• Existing antibodies against the HLA-type of the receiving transplant
(known to the investigator at the time of transplantation)
• History of malignancy during the last 5 years, except squamous or
basal cell carcinoma of the skin, renal cell carcinoma ≤ T1N0M0,
prostate adenocarcinoma ≤ T1N0M0, and adenocarcinoma of the
thyroid
• Thrombocytopenia or leukopenia, uncontrolled hypercholesterolemia,
or hypertriglyceridemia
• Pregnant or nursing (lactating) womenWomen of child-bearing age,
unless they are using effective methods of contraception
HLA human leukocyte antigen
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to moderate-risk patients (CMV-positive donor/CMV-
negative recipients or CMV-positive donor/CMV-positive
recipients). All patients receive prophylactic treatment for
Pneumocystis jirovecii pneumonia with trimethoprim/
sulfamethoxazole for a period of 6 months. All medica-
tions and significant non-drug therapies administered
after the initiation of the study drug are recorded.
Data collection
Patient visits are scheduled at baseline, and at months 1,
3, 6, 9, and 12 post transplantation. A detailed list of all
study assessments and visits is shown in Table 4. Patients
who discontinue the study drug and those who prema-
turely withdraw from the study are scheduled for a visit
and all the assessments listed for visit 6 are performed.
Table 4 Assessment schedule
12-month study period
Month Baseline 1 3 6 9 Premature end of treatment/withdrawal 12
Visit 1 2 3 4 5 6 7
Enrolment
Informed consent X
Inclusion/Exclusion X
Randomisation X
Demography X
General medical history X
Transplantation information X
Viral serology X
Pregnancy test (β-HCG) X
Interventions
Trough levels (everolimus, cyclosporine, tacrolimus) X X X X X X
Assessments
Physical examination X X X
Vital signs X X X X X X X
Study medication check X X X X X X
Haematology/Biochemistry X X X X X X X
Urinalysis X X X X X X
Viral assessments X X X X X X
Serum for non-HLA antibodies and DSA X X X X
Echocardiography (LVH) X X X
Protocol renal allograft biopsya X X X
Biomarker assessmentsb X X X X
CMV substudyb X X X
Wound healing complications As necessary
Rejection episodes
Indicated renal allograft biopsy
Dialysis
AEs/SAEs/Infections/Comments
Concomitant therapy
Immunosuppressive therapy
End of treatment X X
End of study X X
β-HCG human chorionic gonadotropin, AE adverse events, DSA donor-specific antibodies, HLA human leukocyte antigen, LVH left ventricular hypertrophy, SAE severe
adverse events
aNot mandatory. Can be performed according to centre practice
bOnly in selected centres and patients
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Renal function
Renal function is assessed by determining the glomerular
filtrate rate using serum creatinine values according to the
Nankivell formula [42] and used as the primary outcome
measure in the study. In addition, as a secondary efficacy
variable, the glomerular filtration rate is calculated using
the Cockcroft-Gault method [43], the modification of diet
in renal disease (MDRD) method [44–46], and the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
method [47]. Serum creatinine levels are analysed using
venous blood drawn and analysed in the local laboratory.
Outcome measures
BPAR is defined as rejections that are acute and proven
by biopsy. The time to BPAR is the time from random-
isation to the date of first documented BPAR. Graft loss
is defined as a failure to discontinue dialysis or if the pa-
tient undergoes graft nephrectomy. Overall survival is
defined as time from date of randomisation to death due
to any cause. Delayed graft function is defined as the
need for dialysis within the first 7 days post transplant-
ation excluding the first day, and the duration is defined
from the first dialysis day up to the last. Slow graft func-
tion is defined as serum creatinine >3.0 mg/dL at day 5.
Kidney allograft biopsy
Optional allograft biopsies are performed intra-operatively
at the time of transplantation and at month 12. A control
biopsy at month 6 may be performed according to centre
practice. In all cases of suspected acute rejection, a graft
biopsy is performed prior to, or within 24 h of initiation of
anti-rejection therapy. All biopsies are read by the local
pathologist according to the updated Banff 2009 criteria.
Optional biopsies are assessed for the presence of intersti-
tial fibrosis and tubular atrophy using the Banff 2007
criteria.
Non-HLA and HLA antibodies
The presence and evolution of non-HLA and HLA anti-
bodies, and among those especially DSA antibodies in
the serum, is evaluated at a central laboratory. Blood
samples (5 mL) are collected for all patients at baseline,
month 6, and month 12.
LVH and diastolic dysfunction
The echocardiographic analysis included assessments of
the end-diastolic interventricular septum, LV end-diastolic
posterior wall thickness, LV end-diastolic diameter, LV
end-systolic diameter, LV end-diastolic volume, LV end-
systolic volume, LV ejection fraction, relative wall thick-
ness, and LV mass also expressed as LV mass index [48].
LVH was defined as an LV mass index exceeding 110 g/m2
in women and 125 g/m2 in men, and a value of 0.44 was
taken as cut-off point for abnormal relative wall thickness
[49]. Diastolic dysfunction was assessed and graded ac-
cording to the guidelines of the American Society of Echo-
cardiography [50].
CMV substudy
In this optional substudy, 4.7 mL of whole blood is
drawn into a lithium heparin-containing tube at baseline
and at month 12 or at the end of study/treatment, and
shipped on the same day to a central laboratory at 4 °C.
This substudy prospectively monitors the incidence of
viraemia by analysis of viral load, CMV-specific T-cell
frequency, phenotype and functionality, and regulatory
T-cells, and T- and NK-cell subsets.
Data Monitoring Board
An external and independent Data Safety Monitoring
Board was instituted before the start of the study. The
board reviews safety-related issues on an ongoing basis
and is entitled to make recommendations for changes in
study conduct.
Statistical analysis
The primary efficacy variable, i.e., renal function at
month 12 after randomisation between the treatment
groups will be compared with the analysis of covariance
(ANCOVA) model, using the treatment and centre as
factors, and the estimated glomerular filtration rate at
baseline as a covariate. Missing estimated glomerular
filtration values will be handled within the ANCOVA
analysis by multiple imputations by the last available
post-baseline observation carried forward (LOCF) ap-
proach. Assuming a common dropout rate of 20 %, a
sample size of 612 patients (204 patients in each treat-
ment arm) is required in the study, so as to have at
least 80 % power to demonstrate non-inferiority (2.5 %
margin, one-sided t test) for the primary endpoint.
The primary analysis is based on the full analysis set
that consists of all patients who receive at least one dose
of the study drug. The per-protocol set includes all pa-
tients in the full analysis set who do not have any major
deviations from the protocol procedures that may im-
pact the study outcomes. The safety set consists of all
patients who receive at least one dose of the study drug
and had at least one post-baseline safety assessment.
Discussion
ATHENA is one of the largest European multicentre
kidney transplant studies. It is the first study evaluat-
ing the non-inferiority of renal function as a primary
objective in a de novo everolimus-based immunosup-
pressive protocol, and will determine whether an
everolimus-based regimen can preserve renal function
versus the current standard of care. The study will also
Sommerer et al. Trials  (2016) 17:92 Page 10 of 12
provide insights into the evolution of HLA and non-
HLA antibodies, occurrence of viral infections post
transplantation, surveillance of cardiovascular comor-
bidities, and the incidence of wound healing complica-
tions [51]. In addition, the trial explores a regimen of
everolimus with reduced-dose cyclosporine while the
dose of tacrolimus in the everolimus arm and the
standard arm is the same. These unique features will
further enable the study to provide a direct compari-
son between the two arms, which will in turn help in
optimising the immunosuppressive protocols. As the
study addresses a wide range of issues that clinicians
face today, its results are awaited with interest.
Trial status
The study is currently ongoing and actively recruiting
patients across 27 sites, 15 centres in Germany and 12
centres in France. The study is expected to be complete
by March 2016.
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